Literature DB >> 25772590

Innovative clinical trials for development of personalized cancer medicine.

John Mendelsohn1, Ulrik Ringborg2, Richard Schilsky3.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25772590      PMCID： PMC5528749          DOI： 10.1016/j.molonc.2015.02.013

Source DB:  PubMed          Journal:  Mol Oncol        ISSN： 1574-7891            Impact factor:   6.603


× No keyword cloud information.
  4 in total

1.  Innovative clinical trials for development of personalized cancer medicine.

Authors:  John Mendelsohn; Ulrik Ringborg; Richard Schilsky
Journal:  Mol Oncol       Date:  2015-03-05       Impact factor: 6.603

2.  Mouse models of cancer.

Authors:  Anton Berns; Mariano Barbacid
Journal:  Mol Oncol       Date:  2013-02-26       Impact factor: 6.603

Review 3.  Drug resistance to targeted therapies: déjà vu all over again.

Authors:  Floris H Groenendijk; René Bernards
Journal:  Mol Oncol       Date:  2014-05-21       Impact factor: 6.603

4.  The dream and reality of histology agnostic cancer clinical trials.

Authors:  Denis Lacombe; Susen Burock; Jan Bogaerts; Patrick Schoeffski; Vassilis Golfinopoulos; Roger Stupp
Journal:  Mol Oncol       Date:  2014-09-12       Impact factor: 6.603
  4 in total
  3 in total

1.  Innovative clinical trials for development of personalized cancer medicine.

Authors:  John Mendelsohn; Ulrik Ringborg; Richard Schilsky
Journal:  Mol Oncol       Date:  2015-03-05       Impact factor: 6.603

2.  A mission-oriented approach to cancer in Europe: a joint mission/vision 2030.

Authors:  Julio E Celis; Dainius Pavalkis
Journal:  Mol Oncol       Date:  2017-11-09       Impact factor: 6.603

3.  Towards a cancer mission in Horizon Europe: recommendations.

Authors:  Anton Berns; Ulrik Ringborg; Julio E Celis; Manuel Heitor; Neil K Aaronson; Nancy Abou-Zeid; Hans-Olov Adami; Kathi Apostolidis; Michael Baumann; Alberto Bardelli; René Bernards; Yvonne Brandberg; Carlos Caldas; Fabien Calvo; Caroline Dive; Angelika Eggert; Alexander Eggermont; Carolina Espina; Frederik Falkenburg; Jérôme Foucaud; Douglas Hanahan; Ulrike Helbig; Bengt Jönsson; Mette Kalager; Sakari Karjalainen; Miklós Kásler; Pamela Kearns; Klas Kärre; Denis Lacombe; Francesco de Lorenzo; Françoise Meunier; Gerd Nettekoven; Simon Oberst; Péter Nagy; Thierry Philip; Richard Price; Joachim Schüz; Eric Solary; Peter Strang; Josep Tabernero; Emile Voest
Journal:  Mol Oncol       Date:  2020-08       Impact factor: 6.603
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.